We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
0%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$879M
AUM Growth
-$188M
Cap. Flow
-$188M
Cap. Flow %
-21.43%
Top 10 Hldgs %
100%
Holding
51
New
5
Increased
–
Reduced
–
Closed
46

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$237M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$84.4M
3
ARWR icon
Arrowhead Research
ARWR
+$73.3M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$56.2M
5
CDXS icon
Codexis
CDXS
+$48.2M

Sector Composition

Rank Sector Weight
1 Healthcare 0%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTTB icon
26
Q32 Bio
QTTB
$462M
– –
-64,430
Closed -$22.7M
EIGR
27
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-59,709
Closed -$19M
CBAY
28
DELISTED
Cymabay Therapeutics
CBAY
– –
-2,154,934
Closed -$15.4M
KRTX
29
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-325,000
Closed -$6.51M
ORTX
30
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-131,208
Closed -$18.4M
MRTX
31
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-233,045
Closed -$24M
AMRS
32
DELISTED
Amyris Inc.
AMRS
– –
-6,490,557
Closed -$23.1M
AGRX
33
DELISTED
Agile Therapeutics
AGRX
– –
-757
Closed -$2.21M
OBSV
34
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-937,147
Closed -$10.6M
TCDA
35
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-1,424,525
Closed -$56.2M
TMBR
36
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-529
Closed -$189K
SRRA
37
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-60,957
Closed -$1.36M
KDMN
38
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-12,606,605
Closed -$26M
CHMA
39
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-2,377,213
Closed -$17.8M
NBRV
40
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-16,157
Closed -$9.81M
DERM
41
DELISTED
Dermira, Inc.
DERM
– –
-700,000
Closed -$6.69M
MDCO
42
DELISTED
Medicines Co
MDCO
– –
-669,012
Closed -$24.4M
GNCA
43
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-626,401
Closed -$2.46M
SLNOW
44
DELISTED
Soleno Therapeutics, Inc. Series A Warrant
SLNOW
– –
-188,772
Closed -$19K
ZGNX
45
DELISTED
Zogenix, Inc.
ZGNX
– –
-105,000
Closed -$5.02M
SVA
46
DELISTED
Sinovac Biotech, Ltd
SVA
– –
-5,900,000
Closed -$38.2M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Vivo Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Vivo Capital held 51 positions worth $879M, down 18% from $1.07B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Vivo Capital withdrew a net $188M in Q3 2019, closing 46 positions. Its most notable exit was Ascendis Pharma A/S, an estimated $237M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 0% of assets, down from 95% a quarter earlier, followed by Materials.

  • Vivo Capital fully exited Ascendis Pharma A/S in Q3 2019, selling an estimated $237M.
  • Vivo Capital's ten largest holdings make up 100% of its $879M portfolio in Q3 2019.
  • Vivo Capital opened 5 new positions and closed 46 in Q3 2019.
  • Vivo Capital's portfolio value fell 18% quarter-over-quarter to $879M.

Based on Vivo Capital's 13F filing for Q3 2019, filed 13 Nov 2019.